The new centre of excellence will enable DeepVerge to triple its Irish headcount in 2021, hiring for roles in data science, physics and microbiology.
Scientific research company DeepVerge is expanding its data and technology division in Cork, bringing 60 new jobs to the region.
The new facility will include laboratory and engineering production units that will establish a European centre of excellence for real-time detection of multiple dangerous pathogens, including SARS-CoV-2, in water and wastewater systems.
The AI centre will also facilitate the research, development and assembly of the company’s patent pending optofluidic rigs in order to meet immediate and local demand for infrastructural installations of real-time SARS-CoV-2 detection in Ireland and across Europe.
The new roles will see DeepVerge triple its Irish headcount and will be hiring for several high-skilled roles, including epidemiologists, physicists and data scientists.
Founded in 2016, DeepVerge is a science research company that focuses on the production and analysis of bacteria, virus and toxins utilising AI and data analytics.
Rinocloud is the division of DeepVerge that creates AI-based data solutions to solve pervasive threats to the environment and human wellbeing.
Its solutions have been adapted and installed into DeepVerge’s Microtox and Microtrace units, which were originally designed to detect up to 2,700 contaminants in water.
The systems combine technologies such as microfluidics, photonics and AI using proven techniques from micro-engineering, microbiology and artificial intelligence and have typically been used to detect other harmful pathogens such as E coli.
According to DeepVerge, the units now include the ability to immediately identify SARS-CoV-2 contaminants in wastewater.
In March, the European Commission published recommendations on the systematic surveillance of Covid-19 in wastewater.
Last week, the Irish Government announced a National SARS-CoV-2 (Covid-19) Wastewater Surveillance Programme will begin in early May.
DeepVerge’s CEO, Gerry Brandon, said the new facility expands the company’s capability to design produce and assemble instruments on two continents, “playing a key role in Ireland, UK and Europe, detecting and monitoring current and future outbreaks of Covid-19.”